Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · Real-Time Price · USD
2.340
+0.120 (5.41%)
At close: May 12, 2025, 4:00 PM
2.340
0.00 (0.00%)
After-hours: May 12, 2025, 7:58 PM EDT
Alto Neuroscience Employees
Alto Neuroscience had 76 employees as of December 31, 2024.
Employees
76
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$808,303
Market Cap
63.35M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 76 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ANRO News
- 14 days ago - Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach - Business Wire
- 20 days ago - Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day - Business Wire
- 7 weeks ago - Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights - Business Wire
- 2 months ago - The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation - Accesswire
- 2 months ago - Alto Neuroscience to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker - Business Wire
- 3 months ago - Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial - Business Wire
- 3 months ago - The Schall Law Firm Invites Investors With Losses To Join An Investigation Into Alto Neuroscience, Inc. For Securities Fraud - Accesswire